Chemistry:Bemarituzumab
From HandWiki
Revision as of 20:55, 2 January 2022 by imported>StanislovAI (fix)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | FGFR2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number |
Bemarituzumab (INN[1]) is a monoclonal antibody that is being investigated for gastroesophageal junction adenocarcinoma.
This drug is being developed by Five Prime Therapeutics, Zai Lab Limited. (As of 2018), bemarituzumab is undergoing Phase III trials.
References